| Stereochemistry | ABSOLUTE |
| Molecular Formula | C32H29NO5 |
| Molecular Weight | 507.5764 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C2CN([C@@H](CC2=C1OCC3=CC=CC=C3)C(O)=O)C(=O)C(C4=CC=CC=C4)C5=CC=CC=C5
InChI
InChIKey=GHBCIXGRCZIPNQ-MHZLTWQESA-N
InChI=1S/C32H29NO5/c1-37-28-18-17-25-20-33(31(34)29(23-13-7-3-8-14-23)24-15-9-4-10-16-24)27(32(35)36)19-26(25)30(28)38-21-22-11-5-2-6-12-22/h2-18,27,29H,19-21H2,1H3,(H,35,36)/t27-/m0/s1
| Molecular Formula | C32H29NO5 |
| Molecular Weight | 507.5764 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Olodanrigan (EMA-401) is an angiotensin II type 2 receptor antagonist. Olodanrigan may act on paracrine/autocrine mechanisms at peripheral nerve terminals, or intracrine mechanisms, to reduce neuropathic pain signalling in AngII/NGF/TRPV1-convergent pathways. Olodanrigan is being developed by Novartis for the treatment of neuropathic pain.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 0.6 nM [IC50] |
